// App-Quantinova.ai

: Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data

Researchers

Presenter

  • Toby Maher

Principal Investigators

  • Bryony Langford

  • Alex Diamantopoulos

  • Klaus Rohr

  • Mike Baldwin

  • Yoshikazu Inoue

Medical Centers

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Bering Limited, London, United Kingdom

  • Clinical Research Cente, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan,

  • Keck School of Medicine, University of Southern California, Clinical Research, Los Angeles, United States of America

Locations

  • United States

  • Germany

  • United Kingdom

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved